

CLAIMS

1. An anti-gremlin-1 antibody which comprises a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9.
2. The antibody of claim 1, which comprises a HCVR and LCVR sequence pair of SEQ ID NOs: 10/11 or 12/13.
3. The antibody of claim 1, wherein the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences consist of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9 and the remainder of the HCVR and LCVR comprise at least 95% identity to SEQ ID Nos: 10, 11, 12 and/or 13 respectively.
4. The antibody of claim 1 or claim 2, which comprises a heavy and light chain pair of SEQ ID NOs: 14/15, 16/17, 18/19, 22/23, 28/29, 30/31, 32/33, or 34/35.
5. The antibody of claim 1 or claim 2, wherein the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences consist of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9 and the remainder of the heavy and light chains comprise at least 95% identity to SEQ ID NOs: 14, 15, 16 and/or 17 respectively.
6. An antibody according to any one of claims 1-5, which is a chimeric, human or humanised antibody.
7. An antibody according to any one of claims 1-6, which is a Fab, modified Fab, Fab', modified Fab', F(ab')₂, Fv, single domain antibody or an scFv.
8. An isolated polynucleotide encoding an antibody as defined in any one of claims 1-7.
9. An expression vector carrying the polynucleotide of claim 8.

10. A host cell comprising the vector as defined in claim 9.
11. A method of producing the antibody as defined in any one of claims 1-7, comprising culturing the host cell of claim 10 under conditions permitting production of the antibody, and recovering the antibody produced.
12. A pharmaceutical composition comprising an antibody as defined in any one of claims 1-7 and a pharmaceutically acceptable adjuvant and/or carrier.
13. An antibody as defined in any one of claims 1-7 or a pharmaceutical composition as defined in claim 12 for use in a method of treatment of the human or animal body by therapy.
14. The antibody or pharmaceutical composition for use according to claim 13, wherein renal fibrosis such as diabetic nephropathy, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, angiogenesis and/or cancer are treated/prevented.
15. Use of an antibody according to claims 1-7 or a pharmaceutical composition according to claim 12 for the preparation of a medicament for treating or preventing renal fibrosis such as diabetic nephropathy, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, angiogenesis and/or cancer.